Interestingly, the optimum day of CAR-T cell injection after anti-VEGF termination differs from the normalization time, and there is an intermediate point between anti-VEGF initiation and normalization time where the benefits of vascular normalization balance the negative effect of tumor progression. The gene discussed is VEGFA; the disease is neoplasm.